Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company was founded by the previous founders of Emergence Therapeutics. Backed by a syndicate of leading life science investors including Bpifrance Investissement, Kurma Partners, Angelini Ventures, Andera Partners, Pontifax, Surveyor Capital (Citadel), Pureos Bioventures, aMoon, RA Capital Management and DawnBiopharma (KKR).
Location: France
Total raised: $155.44M
Investors 3
| Date | Name | Website |
| 15.09.2025 | aMoon Fund | amoon.fund... |
| 23.10.2025 | Andera Par... | anderapart... |
| 02.08.2024 | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.10.2025 | Series A | $122.8M | Andera Par... |
| 11.06.2024 | Seed | $32.64M | - |
Mentions in press and media 8
| Date | Title | Description |
| 11.01.2026 | Engitix Secures $25M to Advance Cancer, Fibrosis Therapies | British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targete... |
| 08.01.2026 | London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies | Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing. The financing ... |
| 18.11.2025 | T-Therapeutics Secures $91 Million to Advance Bispecific Therapies | T-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence. **T-Therapeutics Secures $91 Million to Advance Bis... |
| 13.11.2025 | Cambridge startup T-Therapeutics secures €27.5 million to improve how the immune system targets disease | T-Therapeutics, a British BioTech company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announced the successful expansion of its Series A financing, raising a further €27.5 million (... |
| 16.10.2025 | Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund | Andera Partners, a leading European private equity player, today announced that it has co-led the Series A financing round of Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC). The trans... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases ... |
| 11.06.2024 | Adcytherix Raises €30M in Seed Funding | Adcytherix, a Marseille, France-based biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC), raised €30M in Seed funding. The round was led by Pontifax with participation from Pureos Bioventures, RA Ca... |
| - | Adcytherix | “Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.” |